News
News, features, and updates
Some innovations are small steps. Others, like the work at Mekonos, open up a world of new possibilities. Follow our adventure.
News Releases
In this newly created role, Benjamin Borgo, MBA, PhD, will be responsible for developing and implementing operational strategies to support the growth and success of the business.
New collaboration combines Mekonos’ novel ex vivo delivery platform with bit.bio’s unique opti-ox™ precision cellular reprogramming technology to accelerate the development of human cells for research, drug discovery and next-generation cell therapies.
Dr. Anil Narasimha, Mekonos CEO & Co-Founder, will present at the annual Cell & Gene Meeting on the Med to be held April 12-14 in Barcelona, Spain and livestreamed globally.
The new collaboration will leverage Mekonos' System on a Chip (SoC) delivery platform with Neochromosome's designer chromosomes to accelerate next-generation cell therapy development.
The new capital will accelerate the development of Mekonos’ System on a Chip (SoC), expand commercial partnerships, and support talent acquisition.
Featured Articles
Fiona Mischel spoke with Anil Narasimha, co-founder and CEO of cell therapy tools company Mekonos, for this year’s check-in on synbio for human health.
Anil Narasimha, CEO & co-founder of Mekonos, talks to Chris Leiter, founder of Atria Ventures, about the company's custom silicon platform for ex vivo molecule delivery and partnering with pharma early on.
‘Success Stories’ from the Bakar Labs Tenant Spotlight Series
We are humbled to have you as a Scientific Advisor for over 4 years and a co-inventor with our founders on a patent. Thank you for your advice and vision that has shaped our thinking on surface chemistry. Our sincerest congratulations!
Launching a health-tech startup is not a sinecure. It takes time, money, and dedication to get the business up to speed.
Mekonos is an innovative biotech startup building solution that enable and accelerate precision medicine, synthetic biology & fundamental science.
Fierce 15 class of 2018 is aimed at advancement—whether it’s simply combining new know-how with old methods, making definitive improvements in well-trodden fields, or pushing us to reconsider how far we can reach with the means available today.
With a wealth of data, a big wallet and partners with connections, Novartis AG opened its first of first digital health lab to tap into and aid health care-related tech startups.
Media Contact
media@mekonos.com